THE HYPERCOAGULATION SYNDROME IN PATIENTS WITH CO-RONOVIRUS INFECTION IN THE POST-COVID PERIOD

Abstract

In the current circumstances when most people are vaccinated the probability of getting COVID-19 is lower, but the consequences of suffering from COVID-19 still pose a serious threat to health. One of the problems is the violation of coagulation balance after the disease. The aim of the research work was to determine changes in coagulation balance and platelet aggregation, total blood count, leukocytosis, leukopenia, thrombocytopenia and thrombocytosis in patients with postcovoid syndrome. The research material was blood obtained on the basis of the Stavropol Regional Clinical Hospital which was taken from the ulnar vein in 75 patients aged 63±13.8 with a confirmed diagnosis of the new coronavirus infection SARS-CoV-2. The ACLTOP500 automatic hemostasis analyzer was used to study coagulation parameters. The following parameters were studied: prothrombin time, activated partial thromboplastin time, fibrinogen, and D-dimer. A study of the parameters of the hemostasis system was conducted. Hypercoagulation was detected in patients with postcovoid syndrome. The presented data demonstrate hyperfibrinogenemia as the most common marker of COVID-associated coagulopathy. The markers of poor disease prognosis are elevated fibrinogen levels along with D-dimer, prothrombin time and activated partial thromboplastin time. A characteristic deviation from the norm requiring hospitalization is an increased level of D-dimer. The identification of laboratory parameters that help to provide an adequate assessment of the severity and prognosis of the disease in COVID-19 patients in a timely manner will make it possible to select effective treatment methods, timely adjust the prescribed therapy and reduce the number of deaths.